Chelsea Therapeutics International is a biopharmaceutical company engaged in acquiring and developing innovative products to treat a variety of human diseases, including disorders of the central nervous system. The company is presently pursuing FDA approval in the United States for Northera (droxidopa), which is a novel, late-stage, orally active therapeutic agent for treating symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure. For more information, visit the company’s Web site: http://www.chelseatherapeutics.com

Let us hear your thoughts below: